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Pleural tumors as sole primary
manifestation of acute
promyelocytic leukemia
A 66-year-old woman was admitted with progressive weakness,
a weight loss of 22 pounds in the last 4 months, and diffuse
thoracic pain. Laboratory analysis revealed anemia of 108 g/l,
normal thrombocytes (242 ·109/l) and normal leukocytes
(4.3 ·109/l). CT scan demonstrated four pleural tumors with
up to 8 cm in diameter without evidence of disease elsewhere
(Figure 1A, B). Bone scintigraphy indicated hot spots over the
ribs on both sides. Biopsy of the pleural tumors showed cells
staining positive for myeloperoxidase, CD34, CD43, CD45 and
lysozyme, indicating myelogenous sarcoma (Figure 1C).
Chromosomal translocations such as t(9;22) (BCR-ABL),
t(8;21) (AML1-ETO), inv(16) (CBFb-MYH11), as well as
mutations of the FLT3 gene were excluded by PCR in cells from
the pleural tumors. Bone marrow biopsy was normal suggesting
the diagnosis of an exclusively extramedullary manifestation of
acute myeloid leukemia (AML) in the pleura. The patient was
treated with two cycles of chemotherapy, including
daunorubicin and cytarabine in the first cycle, and cytarabine
alone in the second cycle. At the end of therapy, CT scan
showed residual pleural tumors of up to 2 cm.
Five months later the patient reported costal pains again.
CT scan demonstrated pleural tumors progressive in size and
number. The patient was admitted because of nasal bleeding
due to severe thrombocytopenia (6 ·109/l). In addition, 64% of
peripheral leukocytes (8.2 ·109/l) were myeloid blasts. The
bone marrow was highly infiltrated with myeloid blasts having
an identical immunophenotype as the cells from the pleural
tumors at diagnosis (Figure 1D, E). A relapse of AML was
diagnosed and a therapy with hydroxyurea was initiated. The
patient died 7 days later of pulmonary infection.
Surprisingly, the cytogenetic analysis at relapse (finished post
mortem) indicated the presence of t(15;17) specific for the
acute promyelocytic leukemia (APL) subtype of AML [1].
Retrospective analysis revealed that PML/RARa transcripts
were detectable in pleural tumors already at diagnosis (Figure
1F). However, bone marrow and peripheral blood at diagnosis
were negative by PCR for PML/RARa transcripts.
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Almost all cases of APL are defined at the molecular level by
the presence of a balanced reciprocal translocation t(15;17)
resulting in the PML-RARa fusion gene [1]. APL is the most
curable subtype of AML [2, 3]. With current therapy, including
all trans retinoic acid (ATRA) and anthracycline-based
chemotherapy, 70%–80% of patients are free of disease at
5 years [2, 3].
Extramedullary disease in APL may occur at relapse, but it is
a very rare clinical event at diagnosis, with half of the reported
cases involving the skin [4, 5]. Other sites involve the central
nervous system, gingival, lymph nodes and spleen. To our
knowledge this is the first report of pleural tumors as sole
extramedullary manifestation of APL at diagnosis. Our case
indicates that determination of t(15;17) should be included
in the panel of markers assessed at diagnosis of all AML
patients, including patients with exclusively extramedullary
AML. This also allows timely diagnosis of APL at unusual
clinical presentation and thus possibly live-saving therapy
with ATRA.
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Figure 1. (A, B) CT scan at diagnosis showing large pleural tumors. (C) Pleural biopsy demonstrating blasts staining positive for myeloperoxidase,
indicating granulocytic sarcoma. (D) Bone marrow aspirate and (E) bone marrow biopsy at relapse, indicating diffuse infiltration with myeloid blasts.
(F) RT-PCR analysis detecting PML-RARa transcripts in the pleural tumors at diagnosis (lane 2) as well as in leukemic blasts at relapse (lane 3).
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